Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06148636 · ClinicalTrials.gov registry record · Early Phase 1
A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors
A Early Phase 1 study of Neuroendocrine Tumors and Neuroendocrine Tumor Grade 2, sponsored by David Bushnell.
- Active
- Registry status
- Early Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT06148636: Active Early Phase 1 study of Neuroendocrine Tumors and Neuroendocrine Tumor Grade 2, sponsored by David Bushnell.
NCT06148636 is a Early Phase 1 study of Neuroendocrine Tumors and Neuroendocrine Tumor Grade 2 that is active but no longer recruiting, run by David Bushnell. The registered enrollment target is 24 participants, below the 179-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06148636, a Early Phase 1 study of Neuroendocrine Tumors and Neuroendocrine Tumor Grade 2, is active but no longer recruiting, sponsored by David Bushnell.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a safety study to determine the recommended dose to test in clinical trials. The study involves two treatments with 212Pb (212-lead) VMT-α-NET. This is a safety study only; it will most likely not provide therapeutic benefit.
Primary Outcome
Determine the recommended phase 2 dose for therapy with \[212Pb\]VMT-Α-NET administered intravenously to patients with neuroendocrine tumors that have progressed despite therapy.
Conditions Studied
Interventions
- DRUG [212Pb] VMT-α-NET
- DIAGNOSTIC_TEST [203Pb] VMT-α-NET SPECT/CT
Study Locations (1)
Iowa
- Holden Comprehensive Cancer Center at the University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2023-11-10 |
| Est. Completion | 2027-12-31 |
| Phase | Early Phase 1 |
What the registry record for NCT06148636 still lists
NCT06148636 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 179-participant average among 52 other Neuroendocrine Tumors trials with a reported enrollment target (87% lower).
The record links to 5 conditions, with Neuroendocrine Tumors appearing as the primary indexed condition, and to 2 interventions - of which [212Pb] VMT-α-NET is the first listed.
NCT06148636 reports a single indexed study location in Iowa.
Frequently Asked Questions
What is clinical trial NCT06148636 about?
NCT06148636 is a clinical study titled "A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors". This is a safety study to determine the recommended dose to test in clinical trials. The study involves two treatments with 212Pb (212-lead) VMT-α-NET. This is a safety study only; it will most likely not provide therapeutic benefit.
What is the current status of trial NCT06148636?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 24 participants. The study started on 2023-11-10. Estimated completion is 2027-12-31.
What conditions does trial NCT06148636 study?
This clinical trial studies the following conditions: Neuroendocrine Tumors, Neuroendocrine Tumor Grade 2, Neuroendocrine Tumor Grade 1, Neuroendocrine Tumor of the Lung, Neuroendocrine Tumor of Pancreas.
What interventions are being tested in trial NCT06148636?
The interventions under investigation include: [212Pb] VMT-α-NET (DRUG), [203Pb] VMT-α-NET SPECT/CT (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06148636?
This trial is sponsored by David Bushnell, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06148636 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuroendocrine Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06148636's enrollment target sits among peer trials
24 41st of 52 higher than 11 of 52 other Neuroendocrine Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neuroendocrine Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors
ACTIVE NOT RECRUITING · Early Phase 1
-
Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver
ACTIVE NOT RECRUITING · Early Phase 1
-
Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective
COMPLETED · Early Phase 1
-
Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI